Percutaneous transluminal stenting for superior vena cava syndrome caused by malignant tumors: a single-center retrospective study

Abstract Objectives To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors. Methods We retrospectively analyzed the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatment in our department from 2015 to 2019 due to malignant tumors and summarized the patient’s sex, age, tumor type, endovascular treatment plan, complications and postoperative follow-up. Results All patients successfully underwent percutaneous intraluminal stent placement with digital subtraction angiography (DSA). Thirty-seven endovascular stents were implanted in 32 patients, including 21 Eluminexx stents, 12 Wallstent stents and 4 covered stents. The technical success rate was 100%, and there were no serious surgery-related complications. The remission rate of clinical symptoms was 53.1% (17/32) at 24 h and 84.4% (27/32) at 48 h. After 48 h, the symptoms of the remaining patients were slowly relieved, and the symptom relief rate was 100% at 7 days. The follow-up period was 1.5–24 months, with an average follow-up period of 6.5 months. During the follow-up, 3 patients had restenosis and 1 patient had secondary thrombosis in the stent. Their symptoms were relieved after the second treatment. Conclusion For superior vena cava syndrome caused by malignant tumors, percutaneous endoluminal stent therapy can quickly and effectively relieve the clinical symptoms of patients, and the incidence of complications is low.

Download Full-text

Percutaneous Transluminal Stenting for Superior Vena Cava Syndrome Caused by Malignant Tumors : A Single Center Retrospective Study

10.21203/rs.3.rs-96027/v1 ◽

2020 ◽

Author(s):

Haitao Liu ◽

Yahua Li ◽

Yang Wang ◽

Lei Yan ◽

Pengli Zhou ◽

...

Keyword(s):

Superior Vena Cava ◽

Stent Placement ◽

Superior Vena Cava Syndrome ◽

Clinical Symptoms ◽

Malignant Tumors ◽

Superior Vena ◽

Vena Cava ◽

Tumor Type ◽

Vena Cava Syndrome

Abstract Objectives：To evaluate the efficacy of percutaneous stent placement in the treatment of superior vena cava syndrome caused by malignant tumors.Methods：To retrospectively analyze the clinical data of 32 patients with superior vena cava syndrome who underwent percutaneous endovascular stent treatment in our department from 2015 to 2019 due to malignant tumors, and summarize the patient’s gender, age, tumor type, endovascular treatment plan, complications and postoperative follow-up.Results：All patients successfully underwent percutaneous intraluminal stent placement with digital subtraction angiography (DSA). Thirty seven endovascular stents were implanted in 32 patients, including 21 Eluminexx stents, 12 Wallstent stents, and 4 covered stents..The technical success rate was 100%, and there were no serious surgery-related complications.The remission rate of clinical symptoms was 53.1% (17 / 32) in 24 hours and 84.4% (27 / 32) in 48 hours. The follow-up period was 1.5-24 months, with an average follow-up period of 6.5 months. During the follow-up, 3 patients had re-stenosis and 1 patient had secondary thrombosis in the stent. The symptoms were relieved after the second treatment.Conclusion: For superior vena cava syndrome caused by malignant tumors, percutaneous endoluminal stent therapy can quickly and effectively relieve the clinical symptoms of patients, and the incidence of complications is low. It should be used as a first-line treatment.

Download Full-text

Superior Vena Cava Rupture during Balloon Angioplasty and Stent Placement to Relieve Superior Vena Cava Syndrome: A Case Report

The Heart Surgery Forum ◽

10.1532/hsf98.20061117 ◽

2007 ◽

Vol 10 (1) ◽

pp. E78-E80 ◽

Cited By ~ 13

Author(s):

Louis Samuels ◽

Joseph Nyzio ◽

John Entwistle

Keyword(s):

Case Report ◽

Superior Vena Cava ◽

Balloon Angioplasty ◽

Stent Placement ◽

Superior Vena Cava Syndrome ◽

Superior Vena ◽

Vena Cava ◽

Vena Cava Syndrome

Download Full-text

Covered Stent Placement for the Treatment of Malignant Superior Vena Cava Syndrome: Is Unilateral Covered Stenting Safe and Effective?

Korean Journal of Radiology ◽

10.3348/kjr.2014.15.1.87 ◽

2014 ◽

Vol 15 (1) ◽

pp. 87 ◽

Cited By ~ 11

Author(s):

Younghoon Cho ◽

Dong Il Gwon ◽

Gi-Young Ko ◽

Heung Kyu Ko ◽

Jin Hyoung Kim ◽

...

Keyword(s):

Superior Vena Cava ◽

Stent Placement ◽

Superior Vena Cava Syndrome ◽

Superior Vena ◽

Vena Cava ◽

Covered Stent ◽

Vena Cava Syndrome

Download Full-text

Pull-Through Technique With Pincer Tactics for Stent Placement in Severe Superior Vena Cava Syndrome

Annals of Vascular Surgery ◽

10.1016/j.avsg.2011.06.014 ◽

2012 ◽

Vol 26 (3) ◽

pp. 421.e11-421.e15 ◽

Cited By ~ 3

Author(s):

Junko Matsushita ◽

Satoru Morita ◽

Kazufumi Suzuki ◽

Hiroaki Inoue ◽

Hajime Yokomizo ◽

...

Keyword(s):

Superior Vena Cava ◽

Stent Placement ◽

Superior Vena Cava Syndrome ◽

Superior Vena ◽

Vena Cava ◽

Vena Cava Syndrome ◽

Pull Through

Download Full-text

Endovascular therapy of acute tumour-related obstruction of the superior vena cava using a self-expanding Nitinol stent

South African Journal of Radiology ◽

10.4102/sajr.v17i4.4 ◽

2013 ◽

Vol 17 (4) ◽

pp. 123-127

Author(s):

Peter Kamusella ◽

Christian Wissgott ◽

Reimer Andresen

Keyword(s):

Superior Vena Cava ◽

Endovascular Therapy ◽

Superior Vena Cava Syndrome ◽

Tumour Progression ◽

Superior Vena ◽

Vena Cava ◽

Bronchial Carcinoma ◽

Nitinol Stent ◽

Vena Cava Syndrome

Objective: To evaluate, in a retrospective study, the clinical efficacy and safety of the self-expanding Nitinol stent in the superior vena cava to alleviate upper venous congestion.Method: In 22 patients (15 men, 7 women), a tumour-related compression of the superior vena cava was diagnosed by spiral CT after intravenous application of contrast medium. Clinically, acute superior vena cava syndrome was found in all patients. Histologically, a bronchial carcinoma was present in 14/22, a lymphoma in 6/22, and mediastinal lymphnode metastases (1 breast carcinoma, 1 malignant melanoma) in 2/22. After a transfemoral approach, cavography was initially performed. The degree of stenosis was classified according to the Stanford classification. In accordance with the degree of stenosis, a self-expanding Nitinol stent was placed.Results: Endovascular stent implantation was conducted without complications in all patients. A marked improvement in acute symptoms was observed clinically within 24 hours in all patients. In the follow-up period of up to 2 years, there were no cases of stent migration. In 7/22 patients, the CT follow-ups revealed tumour progression (3/7 after 3 months, 2/7 after 6 months, and 2/7 after 12 months) with evidence of residual stenosis caused by tumour growth through the stent mesh. During the follow-up period, 15/22 patients died (mean survival 6.4 months).Conclusion: Self-expanding Nitinol stents provide endovascular therapy for superior vena cava syndrome, having a high radial expansive force and the facility to be placed precisely, and alleviating acute, life-threatening symptoms in the palliative situation.

Download Full-text